Published in JAMA Cardiol on November 01, 2016
Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discov (2016) 0.77
Genome Editing in Cardiovascular Biology. Circ Res (2017) 0.75
Tissue Engineering and Regenerative Medicine - New Initiatives for Individual Treatment Offers. Transfus Med Hemother (2016) 0.75
Myocardial Tissue Engineering for Regenerative Applications. Curr Cardiol Rep (2017) 0.75
Exosomes in Cardiovascular Medicine. Cardiol Ther (2017) 0.75
Multimodality molecular imaging in cardiac regenerative therapy. J Nucl Cardiol (2017) 0.75
Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol (2007) 14.48
Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell (2010) 14.18
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol (2013) 11.58
Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet (2004) 9.35
Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell (2010) 7.16
Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med (2009) 5.50
Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A (2012) 4.85
Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat Med (2006) 4.74
Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis. Circulation (2012) 4.56
Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. Nat Biotechnol (2007) 4.53
In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation (2006) 4.48
A nonviral minicircle vector for deriving human iPS cells. Nat Methods (2010) 4.42
Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature (2014) 4.00
Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res (2011) 3.72
Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell (2012) 3.66
Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. Nature (2012) 3.63
Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation (2005) 3.61
A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J (2006) 3.43
Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J (2008) 2.99
Chemically defined generation of human cardiomyocytes. Nat Methods (2014) 2.84
Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma. Nat Clin Pract Oncol (2008) 2.61
Proangiogenic scaffolds as functional templates for cardiac tissue engineering. Proc Natl Acad Sci U S A (2010) 2.58
Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing Pim-1 kinase. Circulation (2009) 2.44
Molecular imaging of cardiac cell transplantation in living animals using optical bioluminescence and positron emission tomography. Circulation (2003) 2.37
Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell (2011) 2.35
Effects of cell number on teratoma formation by human embryonic stem cells. Cell Cycle (2009) 2.30
Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc Natl Acad Sci U S A (2008) 2.25
Differentiation, survival, and function of embryonic stem cell derived endothelial cells for ischemic heart disease. Circulation (2007) 2.21
Embryonic stem cell-derived cardiac myocytes are not ready for human trials. Circ Res (2014) 2.21
Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat Med (2013) 2.10
A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial). Eur Heart J (2015) 2.08
Identification of therapeutic covariant microRNA clusters in hypoxia-treated cardiac progenitor cell exosomes using systems biology. Circ Res (2014) 2.05
Angiomyeloproliferative lesions following autologous stem cell therapy. J Am Soc Nephrol (2010) 2.04
Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. Stem Cell Reports (2014) 2.03
Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circ Res (2012) 2.02
Meta-analysis of cell therapy trials for patients with heart failure. Circ Res (2015) 1.98
Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Reports (2014) 1.90
Genome editing of human embryonic stem cells and induced pluripotent stem cells with zinc finger nucleases for cellular imaging. Circ Res (2012) 1.84
Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis. Eur Heart J (2013) 1.77
Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction. Sci Transl Med (2013) 1.69
Cell therapy for the treatment of coronary heart disease: a critical appraisal. Nat Rev Cardiol (2010) 1.69
Hsp20-engineered mesenchymal stem cells are resistant to oxidative stress via enhanced activation of Akt and increased secretion of growth factors. Stem Cells (2009) 1.60
Stem cell imaging: from bench to bedside. Cell Stem Cell (2014) 1.49
Novel microRNA prosurvival cocktail for improving engraftment and function of cardiac progenitor cell transplantation. Circulation (2011) 1.48
Matrix composition regulates three-dimensional network formation by endothelial cells and mesenchymal stem cells in collagen/fibrin materials. Angiogenesis (2012) 1.47
Design properties of hydrogel tissue-engineering scaffolds. Expert Rev Med Devices (2011) 1.47
CD34(+) cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent. Am Heart J (2011) 1.47
In vivo imaging of embryonic stem cells reveals patterns of survival and immune rejection following transplantation. Stem Cells Dev (2008) 1.46
Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res (2015) 1.39
Genetic and epigenetic stability of human pluripotent stem cells. Nat Rev Genet (2012) 1.38
Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. Eur Heart J (2015) 1.31
Imaging: guiding the clinical translation of cardiac stem cell therapy. Circ Res (2011) 1.30
Electrophysiological challenges of cell-based myocardial repair. Circulation (2009) 1.30
Noninvasive de novo imaging of human embryonic stem cell-derived teratoma formation. Cancer Res (2009) 1.28
Oxygen generating scaffolds for enhancing engineered tissue survival. Biomaterials (2008) 1.24
Cardiovascular molecular imaging: focus on clinical translation. Circulation (2011) 1.24
Human Engineered Heart Muscles Engraft and Survive Long Term in a Rodent Myocardial Infarction Model. Circ Res (2015) 1.21
Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation (2013) 1.16
Genomic instability in pluripotent stem cells: implications for clinical applications. J Biol Chem (2013) 1.13
Early stem cell engraftment predicts late cardiac functional recovery: preclinical insights from molecular imaging. Circ Cardiovasc Imaging (2012) 1.13
Timing of bone marrow cell delivery has minimal effects on cell viability and cardiac recovery after myocardial infarction. Circ Cardiovasc Imaging (2009) 1.08
Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst Rev (2014) 1.06
Safety and Efficacy of Autologous Skeletal Myoblast Sheets (TCD-51073) for the Treatment of Severe Chronic Heart Failure Due to Ischemic Heart Disease. Circ J (2015) 1.02
Cell therapy for human ischemic heart diseases: critical review and summary of the clinical experiences. J Mol Cell Cardiol (2014) 1.00
Hurdles to clinical translation of human induced pluripotent stem cells. J Clin Invest (2015) 0.98
Pluripotent stem cells: immune to the immune system? Sci Transl Med (2012) 0.97
Generation of human iPSCs from human peripheral blood mononuclear cells using non-integrative Sendai virus in chemically defined conditions. Methods Mol Biol (2013) 0.96
Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies. Adv Drug Deliv Rev (2015) 0.91
Novel regenerative therapy using cell-sheet covered with omentum flap delivers a huge number of cells in a porcine myocardial infarction model. J Thorac Cardiovasc Surg (2011) 0.90
Concise Review: Review and Perspective of Cell Dosage and Routes of Administration From Preclinical and Clinical Studies of Stem Cell Therapy for Heart Disease. Stem Cells Transl Med (2015) 0.87
Stem cells. Could it be TIME to abandon BMCs? Nat Rev Cardiol (2012) 0.87
Exosomes in mesenchymal stem cells, a new therapeutic strategy for cardiovascular diseases? Int J Biol Sci (2015) 0.87
Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev (2015) 0.87
Genetic and Epigenetic Regulation of Human Cardiac Reprogramming and Differentiation in Regenerative Medicine. Annu Rev Genet (2015) 0.82
Comparison of Magnetic Resonance Imaging and Serum Biomarkers for Detection of Human Pluripotent Stem Cell-Derived Teratomas. Stem Cell Reports (2016) 0.81
Second generation codon optimized minicircle (CoMiC) for nonviral reprogramming of human adult fibroblasts. Methods Mol Biol (2014) 0.80
Epicardial delivery of VEGF and cardiac stem cells guided by 3-dimensional PLLA mat enhancing cardiac regeneration and angiogenesis in acute myocardial infarction. J Control Release (2015) 0.78
One-year follow-up results from AUGMENT-HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure. Eur J Heart Fail (2015) 0.78